Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End
May 19, 2011
Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End
The CEO of Calando parent firm Arrowhead Research also said that the RNAi shop has restarted preclinical research and development — a notable departure from events in 2009 when the company stopped all such work and shuttered Calando's lab amid a cash crunch.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Promises RNAi Deal, Phase I in 2013 as Investors Voice Worries
August 16, 2012 / Gene Silencing News - Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses
December 22, 2011 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News - 'Not Happy' with Progress of Calando Phase I Solid Tumor Rx, Arrowhead Adding Third Clinical Site
February 17, 2011 / Gene Silencing News